Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating an artificial intelligence AI decision support system called Dermalyser to help primary care physicians distinguish between skin cancer and benign skin lesions. This multicenter randomized controlled trial is conducted at about 30 primary care centers across Sweden, Germany, Scotland, the Netherlands, and Australia. The study aims to assess the accuracy, reliability, and clinical usefulness of Dermalyser in real clinical settings where most patients with skin lesions are managed. Participants will be assessed at primary care centers randomized to either use Dermalyser as a complementary diagnostic tool or follow the standard clinical procedure without AI support. After reaching half of the planned enrollment, centers switch from one phase to the other. Physicians can choose to use Dermalyser when they find it indicated, but the final clinical decision about lesion management remains with the physician. Both groups will be followed for up to five years to track tumor diagnoses, proportions of skin cancer versus benign lesions, and related health outcomes. During the study, participants will have their skin lesions evaluated according to either the AI-supported or standard procedure. The primary outcome measure is the proportion of skin cancers detected within six months of enrollment. Researchers will monitor morbidity and mortality related to skin cancer and compare differences between the groups. Participation may last up to five years with follow-up to assess diagnostic outcomes and safety. The study is sponsored by Linkping University.
Actively Recruiting
Researchers are evaluating the impact of two different guidelines for monitoring labor progress on neonatal and maternal outcomes. The study compares the World Health Organizations Labour Care Guide LCG with standard delivery care in Sweden. The goal is to see if using the LCG can reduce adverse neonatal outcomes and lower the rate of intrapartum Cesarean sections. This study uses a multicenter, stepped-wedge cluster randomized design to explore these effects along with economic considerations and experiences related to childbirth. Participants will receive labor monitoring either according to the WHOs LCG guidelines or standard care. The study will involve multiple delivery units in Sweden, and women in active labor will be randomly assigned to either group as the new guidelines are gradually introduced. Alongside the main study periods, researchers will examine perinatal interventions, labor complications, and collect qualitative data through questionnaires, focus groups, and interviews with women, their partners, and healthcare providers. During participation, women and their partners will be asked about their childbirth experiences, while providers compliance and views on using the LCG will also be assessed. The study will track outcomes such as perinatal mortality, neonatal morbidity, cesarean section rates, and obstetric events like postpartum hemorrhage and labor duration. Data collection and follow-up will occur from 12 weeks up to 18 months after delivery, including economic evaluations and provider experiences to fully understand the effects of the labor monitoring methods.
Actively Recruiting
Researchers are evaluating a new combined procedure to investigate possible coronary heart disease, comparing it to the standard stepwise approach. The study aims to determine if this package investigation, which includes a myocardial perfusion scan, echocardiography, and heart CT scan all done in a single visit, is faster, less costly, or more costly. The trial also looks at how these approaches affect patients physical activity, mental well-being, adherence to heart-protective medications, and risk of cardiac events like heart attacks over several years. The study compares two groups one receiving the package investigation during one hospital visit, and the other undergoing the standard investigation involving sequential tests such as exercise stress bicycle test, echocardiography, and myocardial perfusion scan as needed. Both groups receive resting ECG and risk evaluation before further testing. Additional data from a heart sound recording device Cadscore4 is collected for scientific analysis but not used clinically. Participants are patients from primary care centers with chest symptoms and an intermediate risk for coronary artery disease. They give consent to answer questionnaires at enrollment and at one, three, and five years, and allow researchers access to medical records and registry data. The study measures include time to complete ischemia assessment, costs, health quality, physical fitness, anxiety, depression, medication adherence, and heart events, with follow-up lasting up to five years.
Actively Recruiting
This research aims to assess the impact of tailored exergaming on patients with symptomatic heart failure who are physically inactive. The study focuses on reducing sedentary time, enhancing daily physical activity, improving exercise capacity, decreasing frailty, and boosting health-related quality of life. It involves adult patients receiving standard guideline-directed medical therapy and is structured as a pilot study followed by a multicenter, open-label randomized clinical trial with a six-month follow-up. Participants will be randomly assigned to one of two groups for a three-month period a control group receiving tailored activity advice or an intervention group receiving the Heart-Exergame Heart-eXg. The Heart-eXg is a mobile exergame designed to promote physical activity through farming-themed challenges, adaptable to different mobility levels, and includes social play options. Patients in the intervention group receive feedback and personalized gaming advice from a coach, with weekly feedback in the first month and tailored contact thereafter. Control group participants receive protocol-based activity advice from healthcare professionals. During the study, participants will be introduced to the exergame and monitored using activity trackers. Researchers will assess sedentary time as the primary outcome, with secondary measures including exercise capacity, physical frailty, clinical frailty, and health-related quality of life at baseline, three months, and six months. The study includes assessments of physical activity levels and quality of life, with ongoing feedback and coaching to support adherence. The total participation duration covers active intervention and follow-up periods to evaluate sustained effects.
Actively Recruiting
Researchers are evaluating the plasma expanding effects of three different fluid challenge strategies during longer laparoscopic abdominal surgeries lasting over 90 minutes. The study includes 60 patients randomized into three groups to compare acetated Ringers, albumin 5%, and albumin 20% solutions. The goal is to understand how these fluid treatments affect blood volume and circulation using hemoglobin as an indicator. The study groups receive specific fluid boluses acetated Ringers at 4 mlkg body weight, albumin 5% at 4 mlkg, and albumin 20% at 1 mlkg. After the first bolus infusion during surgery, if cardiac output increases by 10%, a second bolus is given and further studied. Circulatory effects are monitored using a Cardio Q probe inserted into the esophagus, and blood samples are taken at several intervals before and after fluid infusions. Participants undergo various assessments including blood tests for hemoglobin, albumin, and colloid osmotic pressure before surgery and at multiple time points during surgery. Additional measurements include bioimpedance, urine osmolality, and arterial blood gases. Researchers measure plasma volume expansion as the primary outcome at 60 minutes after fluid bolus, along with secondary measures like stroke volume, blood pressure, heart rate, and biochemical markers. The study is expected to conclude by October 2026.
Actively Recruiting
Researchers are observing patients with Gaucher disease in the International Collaborative Gaucher Group ICGG Gaucher Registry to understand the diseases variability, progression, and natural history. The study aims to help guide treatment decisions and improve patient care by providing data on patient outcomes and the long-term effectiveness of treatments like imiglucerase and eliglustat. There is also a Gaucher Pregnancy Sub-registry focusing on pregnancy outcomes and infant growth in women with Gaucher disease. Participants in the Registry do not receive experimental treatments but continue with their usual clinical assessments and care as determined by their physicians. The Pregnancy Sub-registry collects data from pregnant women with Gaucher disease, including medical and obstetric history, pregnancy, birth details, and infant growth up to 36 months postpartum. Both registries do not involve any experimental interventions and support standard care practices. During the study, participants undergo routine clinical assessments and provide medical data as part of their ongoing care. Data collected includes patient outcomes, monitoring recommendations, and pregnancy-related information when applicable. The studys primary outcomes include generating monitoring guidelines for Gaucher disease and tracking pregnancy and infant growth outcomes. The registry is ongoing and international, with data collected over several decades to enhance understanding and optimize care for Gaucher disease.
Actively Recruiting
Researchers are evaluating the effectiveness of Interpersonal Psychotherapy IPT for adolescents aged 15 to 18 years diagnosed with major depression. This study aims to analyze the effects, change mechanisms such as mentalizing and emotion regulation, predictors of treatment success, and how IPT is implemented within child and adolescent psychiatric services. The project plans to include 60 patients over four years and uses a quasi-experimental multiple-baseline design to measure outcomes. Participants will receive Interpersonal Psychotherapy for Adolescents IPT-A, a structured therapy adapted from adult IPT, designed to improve depressive symptoms by enhancing social support and processing interpersonal difficulties. Treatment includes some scheduled meetings with parents and is delivered by trained therapists within the psychiatric service. The study phases include a baseline period with no treatment followed by a treatment phase and a follow-up phase to observe changes. Throughout the study, participants will complete various assessments including the Montgomery sberg Depression Rating Scale and the Patient Health Questionnaire-9, administered at specific times before, during, and after treatment. Therapists and patients will also complete session-by-session measures evaluating mentalizing, emotion regulation, social support, and the working alliance. Qualitative interviews will explore patients experiences of change. The study monitors symptom improvement and predictors of treatment response over time.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.
Actively Recruiting
Researchers are evaluating the effect of spironolactone combined with standard care compared to standard care alone in patients with Heart Failure with Preserved Ejection Fraction HFPEF. This condition is common and serious, but currently lacks effective treatment. The trial is a phase 3 Registry-Randomized Clinical Trial RRCT involving patients from the Swedish Heart Failure Registry and the US. HFPEF is defined by heart failure symptoms, elevated NT-proBNP levels, and an ejection fraction of 40% or higher. Participants will be randomly assigned to receive either spironolactone added to their usual care or usual care alone. Spironolactone will be given as 25 mg tablets, starting at 25 mg per day with a possible increase to 50 mg daily if tolerated. If spironolactone is not tolerated, eplerenone may be prescribed instead. The control group will continue with their standard care without spironolactone. The study duration is planned for 9 years, with enrollment lasting 7 years. During the study, researchers will collect data on cardiovascular death and hospitalizations due to heart failure as the primary outcomes. Secondary outcomes include hospitalizations for various causes, adverse events, and treatment adherence. In Sweden, outcomes will be obtained by linking national registries, while in the US, sites and call centers will report outcomes. The trial aims to enroll approximately 2000 patients, with follow-up continuing for at least 5 years after study start to monitor these outcomes.
1-10 of 16
1